- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | Acrivon Therapeutics stock rating reiterated by Citizens with $13 target | 1 | Investing.com | ||
| 17.11. | Acrivon Therapeutics: Citizens bestätigt Rating "Market Outperform" und Kursziel von 13 US-Dollar | 2 | Investing.com Deutsch | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Acrivon Therapeutics GAAP EPS of -$0.47 beats by $0.12 | 1 | Seeking Alpha | ||
| 13.11. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | 70 | GlobeNewswire (Europe) | Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial... ► Artikel lesen | |
| 13.11. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | Acrivon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Acrivon to present data on AI-driven cancer drug development at conference | 2 | Investing.com | ||
| 01.10. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 89 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing... ► Artikel lesen | |
| 17.09. | Citizens analyst reiterates Market Outperform rating on Acrivon stock | 2 | Investing.com | ||
| 17.09. | Acrivon: Citizens JMP bestätigt "Market Outperform" und Kursziel von 13 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.09. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.08. | Acrivon Therapeutics GAAP EPS of -$0.55 | 1 | Seeking Alpha | ||
| 13.08. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | 269 | GlobeNewswire (Europe) | Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and... ► Artikel lesen | |
| 13.08. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 634 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 292 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 206 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,96 % | Ihre wichtigsten Termine: Heute im Fokus: Bertelsmann, Medtronic, Biontech, Rheinmetall & Imperial Brands | © Foto: Deutsche Börse AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:15... ► Artikel lesen | |
| CUREVAC | 4,340 | -0,73 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AMGEN | 290,05 | -1,02 % | Dividendenbekanntmachungen (21.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,065 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,27 USD 0,2341 EUR ALPHAMIN... ► Artikel lesen | |
| NOVAVAX | 5,566 | -0,86 % | NOVAVAX INC zittert - jetzt entscheidet sich alles! | ||
| BIOGEN | 151,10 | -0,76 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen | |
| MAINZ BIOMED | 0,986 | -6,94 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika
18.11.2025... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,805 | +0,24 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,246 | +1,57 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 61,50 | +0,82 % | How Did Tempus AI Power Its Move to Positive EBITDA in Q3? | ||
| BIOCRYST PHARMACEUTICALS | 6,130 | +1,36 % | BIOCRYST PHARMACEUTICALS INC - S-4, Registration of securities, business combinations | ||
| SAREPTA THERAPEUTICS | 15,425 | +0,46 % | FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings | ||
| BIOMARIN PHARMACEUTICAL | 48,000 | +1,12 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 36,480 | -1,19 % | Wolfe Research initiates Exelixis stock with Peerperform rating | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,837 | -4,91 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| CARDIOL THERAPEUTICS | 0,830 | -1,78 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen |
Das Unternehmen ACRIVON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,300 Euro und damit +1,77 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.